CN114450015A - 用于天然杀伤细胞的增强的扩增和细胞毒性的方法和组合物 - Google Patents

用于天然杀伤细胞的增强的扩增和细胞毒性的方法和组合物 Download PDF

Info

Publication number
CN114450015A
CN114450015A CN202080068418.XA CN202080068418A CN114450015A CN 114450015 A CN114450015 A CN 114450015A CN 202080068418 A CN202080068418 A CN 202080068418A CN 114450015 A CN114450015 A CN 114450015A
Authority
CN
China
Prior art keywords
leu
cells
ser
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080068418.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.B.特拉格
A.L.L.拉泽蒂奇
I.陈
A.沃拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nkarta Inc
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of CN114450015A publication Critical patent/CN114450015A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080068418.XA 2019-07-31 2020-07-29 用于天然杀伤细胞的增强的扩增和细胞毒性的方法和组合物 Pending CN114450015A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962881311P 2019-07-31 2019-07-31
US62/881,311 2019-07-31
US201962932342P 2019-11-07 2019-11-07
US62/932,342 2019-11-07
PCT/US2020/044033 WO2021021907A1 (en) 2019-07-31 2020-07-29 Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Publications (1)

Publication Number Publication Date
CN114450015A true CN114450015A (zh) 2022-05-06

Family

ID=74229259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080068418.XA Pending CN114450015A (zh) 2019-07-31 2020-07-29 用于天然杀伤细胞的增强的扩增和细胞毒性的方法和组合物

Country Status (10)

Country Link
US (1) US20220411754A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003379A4 (cg-RX-API-DMAC7.html)
JP (1) JP7724765B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038439A (cg-RX-API-DMAC7.html)
CN (1) CN114450015A (cg-RX-API-DMAC7.html)
AU (1) AU2020321354A1 (cg-RX-API-DMAC7.html)
CA (1) CA3144724A1 (cg-RX-API-DMAC7.html)
IL (1) IL289902A (cg-RX-API-DMAC7.html)
MX (1) MX2022001255A (cg-RX-API-DMAC7.html)
WO (1) WO2021021907A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113689A (zh) * 2020-08-14 2023-05-12 凯德药业股份有限公司 改善免疫细胞功能

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
IL300903A (en) * 2020-09-02 2023-04-01 Nkarta Inc Expansion and enhanced cytotoxicity of natural killer cells and their uses
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
CA3223666A1 (en) * 2021-07-28 2023-02-02 James Barnaby Trager Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cells
CN116236461B (zh) * 2021-12-08 2026-03-24 深圳先进技术研究院 一种氧化还原型纳米颗粒和活细胞载体及其应用
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024163619A1 (en) * 2023-02-01 2024-08-08 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
WO2025150751A1 (ko) * 2024-01-11 2025-07-17 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭용 배양보조세포 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN107206100A (zh) * 2014-10-27 2017-09-26 弗罗里达中央大学研究基金会 自然杀伤细胞的方法和组合物
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018089476A1 (en) * 2016-11-08 2018-05-17 University Of Central Florida Research Foundation, Inc. Methods and compositions high scale therapeutic production of memory-like nk cells
WO2018182511A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101684456A (zh) * 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
EP3805371A1 (en) * 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206100A (zh) * 2014-10-27 2017-09-26 弗罗里达中央大学研究基金会 自然杀伤细胞的方法和组合物
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
WO2018089476A1 (en) * 2016-11-08 2018-05-17 University Of Central Florida Research Foundation, Inc. Methods and compositions high scale therapeutic production of memory-like nk cells
WO2018182511A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113689A (zh) * 2020-08-14 2023-05-12 凯德药业股份有限公司 改善免疫细胞功能
US12551530B2 (en) 2020-08-14 2026-02-17 Kite Pharma, Inc. Immune cell function

Also Published As

Publication number Publication date
IL289902A (en) 2022-03-01
KR20220038439A (ko) 2022-03-28
JP7724765B2 (ja) 2025-08-18
EP4003379A1 (en) 2022-06-01
JP2022542399A (ja) 2022-10-03
CA3144724A1 (en) 2021-02-04
EP4003379A4 (en) 2023-08-30
MX2022001255A (es) 2022-05-10
AU2020321354A1 (en) 2022-03-03
WO2021021907A1 (en) 2021-02-04
US20220411754A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
JP7724765B2 (ja) ナチュラルキラー細胞の増殖を亢進する、および細胞障害性を増強するための方法および組成物
JP7824934B2 (ja) 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用
EP3895712B1 (en) Engineered natural killer cells and uses thereof
KR102624509B1 (ko) 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
TWI811278B (zh) 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞
ES2643387T3 (es) Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
CN110494558B (zh) Gamma delta t细胞和增强其杀肿瘤活性的方法
CN111163758A (zh) 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂
KR20220041934A (ko) 개선된 기능을 갖는 치료용 면역 세포 및 이의 제조 방법
CN114891117A (zh) 一种靶向ccr8的嵌合抗原受体t细胞及其制备方法和应用
CN115515606A (zh) 修饰的iPSC
CN107427581A (zh) T细胞群的改变方法
RU2839702C2 (ru) Способы и композиции для усиления размножения и цитотоксичности клеток, являющихся натуральными киллерами
Kerr Modulation of T Cells to Promote an Anti-Tumor Response: Activation and Inhibition of T Cells for Efficacy in T-Cell Lymphomas and Melanoma
HK40061900A (en) Engineered natural killer cells and uses thereof
HK40061900B (en) Engineered natural killer cells and uses thereof
WO2024222701A1 (zh) 一种t细胞受体及其用途
WO2021108648A2 (en) Chimeric receptors to cea and methods of use thereof
CA3198363A1 (en) Methods and compositions comprising pd1 chimeric polypeptides
HK40018917B (en) Engineered natural killer cells and uses thereof
HK40018917A (en) Engineered natural killer cells and uses thereof
HK1262291A1 (en) Engineered natural killer cells and uses thereof
HK1262291B (en) Engineered natural killer cells and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination